(-)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]heptanoic acid | 321457-71-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (-)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]heptanoic acid
• 英文别名: 16,16-Difluoro-9,15-dioxoprostan-1-oic acid；7-[(1R,2R)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]heptanoic acid
• CAS: 321457-71-0
• 化学式: C₂₀H₃₂F₂O₄
• 分子量: 374.468
• InChiKey: CTQWVWWSERVGET-HZPDHXFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  26
• 可旋转键数：
  14
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  71.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (-)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]heptanoic acid 在 重氮甲烷 作用下， 以 乙醚 为溶剂， 以72.9%的产率得到11-deoxy-13,14-dihydro-15-keto-16,16-difluoro-PGE1 methyl ester
  参考文献：
  名称：

  Method for treating peripheral vascular diseases

  摘要：

  本发明提供了一种治疗哺乳动物主体的外周血管疾病的方法，包括向需要的患者施用有效量的11-去氧前列腺素化合物。

  公开号：

  US20060247317A1

文献信息

• Process for the preparation of Lubiprostone and intermediates thereof
  申请人：CHIROGATE INTERNATIONAL INC.

  公开号：US10457623B1

  公开（公告）日：2019-10-29

  The present invention relates to a novel process for preparing Lubiprostone and novel intermediates prepared from the process. The process of the present invention does not generate hydrogenated by-products that are difficult to be removed, and thus enables the production of Lubiprostone in an efficient and economical way.

  本发明涉及一种用于制备利扑布曲酮和从该过程中制备的新型中间体的新工艺。本发明的工艺不会产生难以去除的氢化副产物，从而能够以高效和经济的方式生产利扑布曲酮。
• Method for treating central nervous system disorders
  申请人：Ueno Ryuji

  公开号：US20060194880A1

  公开（公告）日：2006-08-31

  The present invention provides a method for treating a central nervous system disorder in a mammalian subject, which comprises administering an effective amount of a 11-deoxy-prostaglandin compound to a subject in need thereof. The invention also provide novel 11-deoxy-prostaglandin compound.

  本发明提供了一种治疗哺乳动物主体中枢神经系统障碍的方法，包括向需要治疗的主体投予有效量的11-去氧前列腺素化合物。本发明还提供了新的11-去氧前列腺素化合物。
• Composition for treating central nervous system disorders
  申请人：Sucampo AG

  公开号：EP2332545A1

  公开（公告）日：2011-06-15

  The present invention provides a method and composition for treating a central nervous system disorder in a mammalian subject, which comprises administering an effective amount of a 11-deoxy-prostaglandin compound to a subject in need thereof. The invention also provide novel 11-deoxy-prostaglandin compound.

  本发明提供了一种用于治疗哺乳动物中枢神经系统疾病的方法和组合物，其中包括向有需要的受试者施用有效量的11-脱氧-前列腺素化合物。本发明还提供了新型 11-脱氧-前列腺素化合物。
• Multilayer beads for pharmaceutical use
  申请人：Sucampo AG

  公开号：US11534404B2

  公开（公告）日：2022-12-27

  Multilayer beads for pharmaceutical use having a drug-in-polymer layer are disclosed. The disclosed multilayer beads for pharmaceutical use have (a) a core particle; (b) an optional barrier layer coated on the surface of the core particle; (c) a drug-in-polymer layer coated on the surface of the core or the barrier layer, (d) an optional sealant layer coated on the surface of the drug-in-polymer layer; and (e) optionally one or more outer layers external to the drug-in-polymer layer or the sealant layer. The drug-in-polymer layer consists essentially of (i) a drug selected from the group consisting of a 15-keto prostaglandin drug, a 13,14-dihydro prostaglandin drug, and a 13,14-dihydro-15-keto prostaglandin drug; and (ii) a polymer selected from the group consisting of polyvinylpyrrolidone, vinylpyrrolidone-vinylacetate copolymer or a mixture thereof. The drug-in-polymer layer may be solid dispersion of the drug in the polymer. Pharmaceutical compositions comprising a plurality of multilayer beads and a pharmaceutically acceptable excipient and methods of treating a gastrointestinal disorder are also disclosed.

  本发明公开了具有聚合体药物层的药用多层微珠。所公开的药用多层微珠具有：(a) 核心颗粒；(b) 涂在核心颗粒表面的任选阻隔层；(c) 涂在核心或阻隔层表面的聚合体药物层；(d) 涂在聚合体药物层表面的任选密封剂层；(e) 聚合体药物层或密封剂层外部的一个或多个外层。药包聚合物层主要包括：(i) 选自 15-酮前列腺素药物、13,14-二氢前列腺素药物和 13,14-二氢-15-酮前列腺素药物组的药物；(ii) 选自聚乙烯基吡咯烷酮、乙烯基吡咯烷酮-乙酸乙烯酯共聚物或其混合物组的聚合物。药物聚合物层可以是药物在聚合物中的固体分散体。还公开了包含多个多层微珠和药学上可接受的赋形剂的药物组合物以及治疗胃肠道疾病的方法。
• A LUBIPROSTONE CRYSTAL, ITS PREPARATION PROCESS AND ITS USE
  申请人：Shanghai Techwell Biopharmaceutical Co., Ltd.

  公开号：EP2275419B1

  公开（公告）日：2017-09-06